Author:
Lindgren Peter,Lindström Jaana,Tuomilehto Jaakko,Uusitupa Matti,Peltonen Markku,Jönsson Bengt,de Faire Ulf,Hellénius Mai-Lis,
Abstract
Objectives: The Finnish Diabetes Prevention Study (DPS) was a randomized intervention program that evaluated the effect of intensive lifestyle modification on the development of diabetes mellitus type 2 in patients with impaired glucose tolerance. As such, a program is demanding in terms of resources; it is necessary to assess whether it would be money well spent. This determination was the purpose of this study.Methods: We developed a simulation model to assess the economic consequences of an intervention like the one studied in DPS in a Swedish setting. The model used data from the trial itself to assess the effect of intervention on the risk of diabetes and on risk factors for cardiovascular disease. Results from the United Kingdom Prospective Diabetes Study were used to estimate the risk of cardiovascular disease and stroke. Cost data were derived from Swedish studies. The intervention was assumed to be applied to eligible patients from a population-based screening program of 60-year-olds in the County of Stockholm from which the baseline characteristics of the patients was used.Results: The model predicted that implementing the program would be cost-saving from the healthcare payers' perspective. Furthermore, it was associated with an increase in estimated survival of .18 years. Taking into consideration the increased consumption by patients due to their longer survival, the predicted cost-effectiveness ratio was 2,363€ per quality-adjusted life-year gained.Conclusions: Lifestyle intervention directed toward high-risk subjects would be cost-saving for the healthcare payer and highly cost-effective for society as a whole.
Publisher
Cambridge University Press (CUP)
Reference32 articles.
1. Diabetes in Mexico–A serious and growing problem;Phillips;World Health Stat Q.,1992
2. Global and societal implications of the diabetes epidemic
3. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
4. Metabolic syndrome and breast cancer risk;Sinagra;Eur Rev Med Pharmacol Sci.,2002
5. UKPDS 60
Cited by
75 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献